Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 266

1.

Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HH, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr.

2.

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

Kumarasamy N, Aga E, Ribaudo HJ, Wallis CL, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Bartlett JA.

Clin Infect Dis. 2015 May 15;60(10):1552-8. doi: 10.1093/cid/civ109. Epub 2015 Feb 18.

PMID:
25694653
3.

HIV drug resistance mutations in proviral DNA from a community treatment program.

Derache A, Shin HS, Balamane M, White E, Israelski D, Klausner JD, Freeman AH, Katzenstein D.

PLoS One. 2015 Jan 30;10(1):e0117430. doi: 10.1371/journal.pone.0117430. eCollection 2015.

4.

The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time.

Tang MW, Clemons KV, Katzenstein DA, Stevens DA.

Crit Rev Microbiol. 2015 Jan 23:1-9. [Epub ahead of print]

PMID:
25612826
5.

Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, Pillay D, Hoffmann C, Katzenstein D, Shafer RW, Morris L.

Antimicrob Agents Chemother. 2015 Feb;59(2):960-71. doi: 10.1128/AAC.04215-14. Epub 2014 Nov 24.

PMID:
25421485
6.

HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.

Kantor R, DeLong A, Balamane M, Schreier L, Lloyd RM Jr, Injera W, Kamle L, Mambo F, Muyonga S, Katzenstein D, Hogan J, Buziba N, Diero L.

J Int AIDS Soc. 2014 Nov 18;17:19262. doi: 10.7448/IAS.17.1.19262. eCollection 2014.

7.

Drug resistance mutations from whole blood proviral DNA among patients on antiretroviral drugs in Zimbabwe.

Chimukangara B, Gwanzura L, Mitchell R, Katzenstein D, Masimirembwa C.

Curr HIV Res. 2014;12(5):309-16.

PMID:
25323793
8.

Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253.

Shiboski CH, Chen H, Ghannoum MA, Komarow L, Evans S, Mukherjee PK, Isham N, Katzenstein D, Asmelash A, Omozoarhe AE, Gengiah S, Allen R, Tripathy S, Swindells S; AIDS Clinical Trials Group Network and Oral HIV/AIDS Research Alliance.

Int J Tuberc Lung Dis. 2014 Jun;18(6):682-8. doi: 10.5588/ijtld.13.0729.

9.

Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Liang EC, Sceats L, Bayless NL, Strauss-Albee DM, Kubo J, Grant PM, Furman D, Desai M, Katzenstein DA, Davis MM, Zolopa AR, Blish CA.

J Virol. 2014 Aug;88(15):8629-39. doi: 10.1128/JVI.01257-14. Epub 2014 May 21.

10.

Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

Wallis CL, Aga E, Ribaudo H, Saravanan S, Norton M, Stevens W, Kumarasamy N, Bartlett J, Katzenstein D; A5230 team.

Clin Infect Dis. 2014 Sep 1;59(5):706-15. doi: 10.1093/cid/ciu314. Epub 2014 May 1.

PMID:
24795328
11.

An affordable HIV-1 drug resistance monitoring method for resource limited settings.

Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Mkhize C, Lessells RJ, Seebregts C, de Wit TF, Viljoen J, Katzenstein D, De Oliveira T.

J Vis Exp. 2014 Mar 30;(85). doi: 10.3791/51242.

12.

HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.

Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, Cu-Uvin S, D'Aquila R, Frenkel L, Fiscus S, Coombs R; ACTG A5077 Study Team.

PLoS One. 2014 Apr 3;9(4):e93537. doi: 10.1371/journal.pone.0093537. eCollection 2014.

13.

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D.

HIV Clin Trials. 2013 Nov-Dec;14(6):284-91. doi: 10.1310/hct1406-284.

14.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.

15.

HIV RNA and genotype in resource-limited settings: can we do better?

Katzenstein DA.

Clin Infect Dis. 2014 Jan;58(1):110-2. doi: 10.1093/cid/cit634. Epub 2013 Sep 27. No abstract available.

16.

Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.

Land S, Zhou J, Cunningham P, Sohn AH, Singtoroj T, Katzenstein D, Mann M, Sayer D, Kantor R.

J Int AIDS Soc. 2013 Jul 10;16:18580. doi: 10.7448/IAS.16.1.18580.

17.

Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1.

Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW.

Antimicrob Agents Chemother. 2013 Jun 24. [Epub ahead of print]

18.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

19.

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC.

PLoS One. 2013 Apr 17;8(4):e61102. doi: 10.1371/journal.pone.0061102. Print 2013.

20.

Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253.

Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, Gupta A, Veloso VG, Asmelash A, Omoz-Oarhe AE, Gengiah S, Lalloo U, Allen R, Shiboski C, Andersen J, Qasba SS, Katzenstein DK; AIDS Clinical Trials Group 5253 Study Team.

Int J Tuberc Lung Dis. 2013 Apr;17(4):532-9. doi: 10.5588/ijtld.12.0737.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk